当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.

Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.

Abstract：

:The activity of selective estrogen receptor modulators (SERMs) is not fully explained by an estrogen receptor (ER) switch model that simply turns estrogen activity on or off. A better understanding of the mechanisms involved in estrogen signaling and the development of drug resistance could help stratify patients into more coherent treatment groups and identify novel therapeutic candidates. This review describes how interactions between two novel factors known to influence estrogenic activity: nuclear receptor cofactors--protein partners which modulate estrogen action, and microRNAs--a class of recently discovered regulatory elements, may impact hormone-sensitive breast cancer. The role of nuclear receptor cofactors in estrogen signaling and the associations between ER cofactors and breast cancer are described. We outline the activity of microRNAs (miRNAs) and their associations with breast cancer and detail recent evidence of interactions between the ER and its cofactors and miRNA and provide an overview of the emerging field of miRNA-based therapeutics. We propose that previously unrecognised interactions between these two species of regulatory molecules may underlie at least some of the heterogeneity of breast cancer in terms of its clinical course and response to treatment. The exploitation of such associations will have important implications for drug development.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

McCafferty MP,McNeill RE,Miller N,Kerin MJ

doi

10.1007/s10549-009-0429-7

subject

Has Abstract

pub_date

2009-08-01 00:00:00

pages

425-32

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

116

pub_type

杂志文章,评审

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract：:This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-1332-y

    authors： Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期：2011-04-01 00:00:00

  • Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

    abstract：PURPOSE:Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4178-8

    authors： Conway K,Edmiston SN,Parrish E,Bryant C,Tse CK,Swift-Scanlan T,McCullough LE,Kuan PF

    更新日期：2017-06-01 00:00:00

  • SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.

    abstract：:It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we ev...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1625-9

    authors： Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

    更新日期：2012-04-01 00:00:00

  • Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.

    abstract：:The rate of contralateral prophylactic mastectomy (CPM) is rising rapidly, despite limited evidence about the procedure's relative benefits and harms. The objective of this study is to examine the impact of CPM on life expectancy (LE) and quality-adjusted life expectancy (QALE) in women with sporadic unilateral breast...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3462-8

    authors： Lester-Coll NH,Lee JM,Gogineni K,Hwang WT,Schwartz JS,Prosnitz RG

    更新日期：2015-07-01 00:00:00

  • The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40.

    abstract：:Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1012942910375

    authors： Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

    更新日期：2001-11-01 00:00:00

  • Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.

    abstract：BACKGROUND:Three tools are currently available to predict the risk of contralateral breast cancer (CBC). We aimed to compare the performance of the Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast cancer (BC). METHODS:We analyzed data of 132,756 patients (4682 CBC) from 20 international stu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05611-8

    authors： Giardiello D,Hauptmann M,Steyerberg EW,Adank MA,Akdeniz D,Blom JC,Blomqvist C,Bojesen SE,Bolla MK,Brinkhuis M,Chang-Claude J,Czene K,Devilee P,Dunning AM,Easton DF,Eccles DM,Fasching PA,Figueroa J,Flyger H,García-Cl

    更新日期：2020-06-01 00:00:00

  • Tamoxifen aziridine binding to cytosolic proteins from human breast specimens is negatively associated with estrogen receptors, progesterone receptors, pS2, and cathepsin-D.

    abstract：:[3H]Tamoxifen Aziridine ([3H]TAZ) is a derivative of the antiestrogen tamoxifen that covalently labels the Estrogen Receptor (ER), and perhaps other uncharacterized proteins. In a previous article we described that [3H]TAZ binds to a cytosolic protein from human uterine tissues that shares some, but not all, the ER pr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006062510883

    authors： Navarro D,Doreste H,Cabrera JJ,Morales M,Díaz-Chico JC,Díaz-Chico BN

    更新日期：1998-07-01 00:00:00

  • Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.

    abstract：PURPOSE:This study aimed to examine the prevalence and trends of breast cancer-related risk factors and characteristics in premenopausal underweight Korean women according to birth year cohort. METHODS:Socioeconomic and breast cancer-related risk factors were investigated in 13,415 premenopausal women using nationwide...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05091-x

    authors： Kim JH,Yoon KH,Hur H,Park S,Kim JY,Park HS,Kim SI,Cho YU,Park BW

    更新日期：2019-04-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract：:Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666210

    authors： LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期：1994-01-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

    abstract：PURPOSE:The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). However, the studies in the overview were to a large content performed before mode...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4007-5

    authors： Nordenskjöld A,Fohlin H,Fornander T,Löfdahl B,Skoog L,Stål O

    更新日期：2016-11-01 00:00:00

  • The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

    abstract：:Platinum agents such as cisplatin and carboplatin are DNA-damaging agents with activity in breast cancer (BC), particularly in the triple negative (TN) subgroup. The utility of platinum agents, in addition to standard neoadjuvant chemotherapy (NAC), is controversial. To assess the activity of platinum agents in patien...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-014-2876-z

    authors： Petrelli F,Coinu A,Borgonovo K,Cabiddu M,Ghilardi M,Lonati V,Barni S

    更新日期：2014-04-01 00:00:00

  • Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?

    abstract：PURPOSE:The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician's decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralatera...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4426-y

    authors： Jonna AR,Sam KQ,Ebuoma LO,Sedgwick EL,Wang T,Benveniste AP

    更新日期：2017-11-01 00:00:00

  • Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer.

    abstract：:The androgen receptor (AR) is a transcription factor mediating the action of androgens. The AR gene is localized on chromosome X and it contains a series of CAG trinucleotide repeats. The length of the CAG repeats varies among individuals and this polymorphism is believed to be related to AR transcriptional activity. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006356502820

    authors： Yu H,Bharaj B,Vassilikos EJ,Giai M,Diamandis EP

    更新日期：2000-01-01 00:00:00

  • Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

    abstract：BACKGROUND:Central nervous system (CNS) relapse is increasing in breast cancer. This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype. METHODS:To determine the factors associated with clinic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-0999-3

    authors： Carey LA,Ewend MG,Metzger R,Sawyer L,Dees EC,Sartor CI,Moore DT,Graham ML

    更新日期：2004-12-01 00:00:00

  • A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.

    abstract：:A model for a more precise prognosis of the risk of relapse is needed to avoid overtreatment of lymph node-negative breast cancer patients. A large derivation data set (n = 684) was generated by pooling three independent breast cancer expression microarray data sets. Two major prognostic factors, proliferation and imm...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1626-8

    authors： Oh E,Choi YL,Park T,Lee S,Nam SJ,Shin YK

    更新日期：2012-04-01 00:00:00

  • Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

    abstract：:The prognostic value of proliferative activity and its relationship with steroid hormone receptors and histopathological grade have been demonstrated for breast cancers. However, nothing is known about the underlying mechanisms. In order to understand the chronology of the appearance of increased proliferative activit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01831474

    authors： Remvikos Y,Gerbault-Seureau M,Magdelénat H,Prieur M,Dutrillaux B

    更新日期：1992-01-01 00:00:00

  • Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

    abstract：:Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2791-8

    authors： García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

    更新日期：2014-01-01 00:00:00

  • HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

    abstract：BACKGROUND:Several recent epidemiologic studies examined the association between breast cancer risk and an inherited, single-nucleotide polymorphism in the HER2 gene, codon 655 G to A, which leads to an amino acid substitution of Ile to Val. Results of previous studies have been mixed, with most studies showing no asso...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1024068525763

    authors： Millikan R,Eaton A,Worley K,Biscocho L,Hodgson E,Huang WY,Geradts J,Iacocca M,Cowan D,Conway K,Dressler L

    更新日期：2003-06-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract：:The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2035-3

    authors： Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期：2012-07-01 00:00:00

  • Alcohol consumption and breast cancer risk in Japanese women: the Miyagi Cohort study.

    abstract：:Alcohol consumption is known to be a risk factor for breast cancer in Western countries, but few epidemiologic data have been available in Japan. This population-based prospective cohort study evaluated the associations of alcohol consumption with breast cancer risk in a Japanese population. A total of 19,227 women ag...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1381-x

    authors： Kawai M,Minami Y,Kakizaki M,Kakugawa Y,Nishino Y,Fukao A,Tsuji I,Ohuchi N

    更新日期：2011-08-01 00:00:00

  • Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

    abstract：:Since our previous findings had indicated that the androgenic steroid medroxyprogesterone acetate (MPA) exerts potent inhibitory effects on 7,12-dimethylbenz(a)anthracene (DMBA)-induced tumor growth, we have studied the effect of low doses of MPA released from Depo-Provera and from 50:50 poly[DL-lactide-co-glycolide] ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01961245

    authors： Li S,Lepage M,Mérand Y,Bélanger A,Labrie F

    更新日期：1992-01-01 00:00:00

  • A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.

    abstract：:Cognitive impairment, especially verbal episodic memory and executive function impairments, has been considered to be a possible adverse effect of aromatase inhibitors (AI). This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learning test-RAVLT) and o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3493-1

    authors： Le Rhun E,Delbeuck X,Lefeuvre-Plesse C,Kramar A,Skrobala E,Pasquier F,Bonneterre J

    更新日期：2015-08-01 00:00:00

  • Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: a reappraisal.

    abstract：:A review of the current literature on immunohistologic and histochemical methods for the detection of steroid hormone binding sites in breast cancer, reveals that many, but not all of the criteria for establishing hormone-receptor binding interactions have been met. These include tissue specificity, binding between la...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806746

    authors： Pertschuk LP,Tobin EH,Carter AC,Eisenberg KB,Leo VC,Gaetjens E,Bloom ND

    更新日期：1981-01-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract：:Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006190820231

    authors： Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期：1999-02-01 00:00:00

  • A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

    abstract：:Decreased CYP2D6 activity is associated with lower levels of active tamoxifen metabolites. We examined the impact of CYP2D6 genotype on tamoxifen pharmacokinetics, biomarker activity, and efficacy in a pooled analysis of low-dose tamoxifen. Four randomized breast cancer prevention trials of very-low-dose (1 mg/day, n ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3932-7

    authors： Johansson H,Gandini S,Serrano D,Gjerde J,Lattanzi M,Macis D,Guerrieri-Gonzaga A,Aristarco V,Mellgren G,Lien E,DeCensi A,Bonanni B

    更新日期：2016-08-01 00:00:00

  • Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

    abstract：PURPOSE:The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality of life after the end of chemotherapy. METHODS:We included 135 newly diagn...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4720-3

    authors： de Vries YC,Boesveldt S,Kelfkens CS,Posthuma EE,van den Berg MMGA,de Kruif JTCM,Haringhuizen A,Sommeijer DW,Buist N,Grosfeld S,de Graaf C,van Laarhoven HWM,Kampman E,Winkels RM

    更新日期：2018-07-01 00:00:00

  • Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

    abstract：:Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805741

    authors： Nagasawa H,Aoki M,Sakagami N,Ishida M

    更新日期：1988-09-01 00:00:00

  • Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.

    abstract：:Mammographic density is a strong and independent risk factor for breast cancer and is considered an intermediate marker of risk. The major predictors of premenopausal mammographic density, however, have yet to be fully elucidated. To test the hypothesis that urinary estrogen metabolism profiles are associated with mam...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2240-0

    authors： Bertrand KA,Eliassen AH,Hankinson SE,Gierach GL,Xu X,Rosner B,Ziegler RG,Tamimi RM

    更新日期：2012-11-01 00:00:00

  • HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

    abstract：BACKGROUND:Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-019-05303-y

    authors： Jerusalem G,Lancellotti P,Kim SB

    更新日期：2019-09-01 00:00:00